The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ...

A new oral insulin embedded in sugar-free chocolate uses nano-carriers to target the liver, cutting hypoglycemia risk. The ...

SEC asks Abbvie to conduct Phase III study on subcutaneous drug for Parkinson's disease: Our Bureau, New Delhi Friday, July 3, 2026, 08:00 Hrs [IST] A Subject Expert Committee (SE ...

Key market opportunities for SKYRIZI include its expansion across multiple indications such as psoriasis and IBD, showcasing best-in-class efficacy and strong clinical responses. Strategic positioning ...

Explore how space oncology could transform cancer treatment through microgravity research and innovative drug development ...

Adults with dangerously elevated blood fats now have the first approved drug shown to cut their risk of acute pancreatitis, a ...

Many of the FDA’s decisions this quarter involve applications that have previously been delayed, declined or outright ...

Tennessee's lethal injection protocol adopted a year and a half ago appears to include reduced training in IV placement. That ...

If you’re considering taking a GLP-1 (glucagon-like peptide-1) receptor agonist for weight loss, here’s what to know about the long-term benefits and risks, along with insights from physicians. GLP-1 ...

Xeris Biopharma Holdings, Inc. , a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today ...